Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma-Reference-Cited by-同舟云学术

Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma

Published:2020-09-04 Issue:6 Volume:112 Page:817-824
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Suzuki Yasuhiro^ORCID,Yano Takahiro,Suehiro Youko,Iwasaki Hiromi,Hidaka Michihiro,Otsuka Maki,Sunami Kazutaka,Ikeda Hirokazu,Sawamura Morio,Ito Takuo,Iida Hiroatsu,Nagai Hirokazu

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12185-020-02987-7.pdf

Reference31 articles.

1. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30.

2. Ellin F, Landstrom J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124:1570–7.

3. Yamaguchi M, Suzuki R. JSH practical guidelines for hematological malignancies, 2018: 7. Peripheral T-cell lymphoma (PTCL). Int J Hematol. 2019;109:137–40.

4. O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182–9.

5. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631–6.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 2 study of pegylated liposomal doxorubicin plus cyclophosphamide, vincristine/vindesine, and prednisone in newly diagnosed PTCL: 8-year results;The Oncologist;2024-05-31

2. The prognostic significance of POD24 in peripheral T-cell lymphoma;Hematology;2024-01-22

3. Identification of leukocyte-lymphocyte ratio as a novel prognostic factor in Peripheral T-cell lymphoma;Holistic Integrative Oncology;2023-10-26

4. The clinical features, treatment, and prognostic factors for peripheral T‐cell lymphomas: A single‐institution analysis of 240 Chinese patients;Asia-Pacific Journal of Clinical Oncology;2022-07-12

5. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2022-03